EFFECTS OF CYP2C19 AND P2Y12 GENE POLYMORPHISMS ON CLINICAL RESULTS OF PATIENTS USING CLOPIDOGREL AFTER ACUTE ISCHEMIC CEREBROVASCULAR DISEASE

dc.contributor.authorŞen, Halil Murat
dc.contributor.authorSılan, Fatma
dc.contributor.authorSılan, Coşkun
dc.contributor.authorDeğirmenci, Yıldız
dc.contributor.authorKaraman, Handan Işın Özışık
dc.date.accessioned2020-05-01T09:11:54Z
dc.date.available2020-05-01T09:11:54Z
dc.date.issued2014
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionsilan, coskun/0000-0002-8352-6571; Silan, Coskun/0000-0002-8352-6571en_US
dc.descriptionWOS: 000352978700004en_US
dc.descriptionPubMed: 25937796en_US
dc.description.abstractThe CY2C19 and P2Y12 gene polymorphisms are responsible for resistance to clopidogrel, known as drug unresponsiveness. In this study we researched the effect of gene polymorphism on clinical results of patients who began clopidogrel therapy after acute ischemic cerebrovascular disease. The study included 51 patients. The patient group included patients who had begun prophylactic clopidogrel due to acute ischemic cerebrovascular disease in the last 2 years. All patients were monitored by the Neurology Outpatient Clinic at Canakkale Onsekiz Mart University Research Hospital, Canakkale, Turkey, and only those monitored for at least 1 year were included in the study. When the *1, *2 and *3 alleles of the CYP2C19 gene polymorphism were evaluated, two patients were homozygotes for *2/*2, 13 patients were heterozygous for *1/*2 and 36 patients were homozygotes for the wild type *1/*1. No patient had the *3 allele. Three heterozygous patients, one for *2/*2 and two for *1/*2, stopped clopidogrel therapy due to repeated strokes and began taking warfarin. When evaluating P2Y12 52 (G>T) and 34 (C>T) polymorphisms, all alleles were of the wild type. The CYP2C19 and P2Y12 gene polymorphisms may cause recurring strokes linked to insufficient response to treatment of ischemic cerebrovascular disease. In our patient group, three patients suffered repeated strokes and these patients had the CYP2C19*2 gene polymorphism. As a result, before medication use, genetic testing is important for human life, quality of life and economic burden.en_US
dc.description.sponsorshipDepartment of Scientific Research Projects Commission, Canakkale Onsekiz Mart University, Canakkale, TurkeyCanakkale Onsekiz Mart Universityen_US
dc.description.sponsorshipThe present study was supported by the Department of Scientific Research Projects Commission, Canakkale Onsekiz Mart University, Canakkale, Turkey. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.en_US
dc.identifier.doi10.2478/bjmg-2014-0072en_US
dc.identifier.endpage41en_US
dc.identifier.issn1311-0160
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage37en_US
dc.identifier.urihttps://doi.org/10.2478/bjmg-2014-0072
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5809
dc.identifier.volume17en_US
dc.identifier.wosWOS:000352978700004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMacedonian Acad Sciences Artsen_US
dc.relation.ispartofBalkan Journal Of Medical Geneticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIschemic cerebrovascular disease (ICVD)en_US
dc.subjectclopidogrelen_US
dc.subjectCYP2C19 and P2Y12 gene polymorphismsen_US
dc.titleEFFECTS OF CYP2C19 AND P2Y12 GENE POLYMORPHISMS ON CLINICAL RESULTS OF PATIENTS USING CLOPIDOGREL AFTER ACUTE ISCHEMIC CEREBROVASCULAR DISEASEen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
5809.pdf
Boyut:
215.91 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text